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Summary statement 28 
We used plsmid DNA like as LacZ DNA or NIS DNA which are internally translated in the 29 
cells, which can be loaded on MHC I, not be secreted. We clarify reversion of immunity from 30 
Th2 to Th1 when we repeated intradermal injection of plasmid DNA as a DNA vaccine. 31 
 32 
 33 




In evaluating the effectiveness of DNA vaccines, it is important to (1) monitor the movement 36 
of cells transfected with the injected plasmid DNA; and (2) overcome immune deviation, which 37 
causes a switch from helper T cell (Th)1 to Th2. Mouse CT26 cells were transfected with the 38 
pcDNA-hNIS vector expressing human sodium/iodide symporter (hNIS) gene; the pCMV-39 
LacZ vector expressing β-galactosidase from the cytomegalovirus promoter was used for 40 
imaging. Transgene expression was monitored by X-gal staining or γ-ray detection. Whole-41 
body images were obtained by nuclear scintigraphy following intraperitoneal injection of 42 
radioactive technetium (99mTc). Migrating cells expressing hNIS or LacZ were monitored for 2 43 
weeks. Reverse transcription PCR revealed that cells expressing the transgenes had moved out 44 
of the injection site. HNIS-expressing cells were observed specifically in peripheral lymphoid 45 
tissues, especially in draining lymph nodes and spleen. LacZ DNA was detected with a specific 46 
antibody in immunized mice that exhibited Th2-type immunity. IgG2a type was predominant 47 
in hNIS-immunized mice, as determined by enzyme-linked immunosorbent assay (ELISA). 48 
Moreover, the vaccine caused increases in the IgG2a/IgG1 ratio, number of interferon (IFN)-49 
γ-secreting cells (by enzyme-linked immunospot assay), and IFN-γ level (by cytokine ELISA) 50 
in the supernatant of immune cells. Tumor growth was retarded in mice that were immunized 51 
with hNIS DNA followed by inoculation with CT26/NIS cells. The movement of mouse cells 52 
transfected with plasmid DNA was restricted to immune organs. Transgene expression in these 53 
cells was detected for at least 2 weeks post immunization. Repeated intradermal injection of 54 








DNA vaccines can induce both cellular and humoral immunity and are considered as an 61 
attractive immunization strategy to protect against infection, autoimmunity, and cancer 62 
(Manthorpe et al., 1993; Ulmer et al., 1993; Wolff et al., 1990). The LacZ gene encoding β-63 
galactosidase (β-gal) has been used as a reporter for long-term imaging in gene therapy 64 
experiments (Boland et al., 2000; Cho et al., 2002; Min et al., 2002). DNA vaccine injected 65 
into a target site and internalized by antigen-presenting cells (APCs) without being degraded 66 
can elicit a strong immune response in the host (Son et al., 2016a). The fate of injected DNA 67 
vaccines can be monitored by examining their distribution or expression in the host (Donnelly, 68 
Berry & Ulmer. 2003). For instance, DNA vaccines using LacZ injected via various routes has 69 
been detected and shown to persist at the injection site as well as in other organs. 70 
Biodistribution is primarily investigated by in situ hybridization, immunohistochemistry, and 71 
reverse transcription (RT)-PCR, which require that experimental animals be sacrificed and their 72 
organs isolated to confirm gene expression levels. In vivo imaging is required in order to 73 
analyze gene expression following DNA vaccination in living animals. 74 
Vaccination with the human sodium/iodide symporter (hNIS) gene combined with in 75 
vivo monitoring has dual benefits—i.e., targeted immunotherapy against NIS-expressing 76 
cancer cells and the ability to evaluate vaccine efficacy by scintigraphic imaging (Son et al., 77 
20167; Jeon et al., 2007; Jeon et al., 2008).  99mTechnetium (99mTc) emits γ-rays; hNIS labeled 78 
with 124I, 125I, 131I, or 99mTc has allowed the visualization of various biochemical processes in 79 
the tissues of living subjects (Son et al., 2016a). 80 
We used LacZ and NIS as reporter genes to monitor immune responses following DNA 81 
immunization. Cytoplasmic LacZ and transmembrane NIS proteins are translated and retained 82 
in cells without being secreted. Moreover, they can be loaded onto major histocopatibility 83 
complex class (MHC-)I after translation and onto MHC-II after engulfment by APCs, thereby 84 
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stimulating helper T cell (Th)1 and Th2 immune responses, and finally avoiding immune 85 
deviation (Son et al., 2016b). 86 
Modulating the tumor microenvironment is a critical aspect of cancer immunotherapy 87 
(Kuol et al., 2017). hNIS has been used to overcome the challenges posed by the complexity 88 
of the tumor microenvironment. Expression of NIS—a specialized active iodide transporter 89 
(Chungl, 2002; De La Vieja et al., 2000)—results in the accumulation of therapeutic 90 
radionucleotides in cancer cells (Chen et al., 2006; Mandell, Mandell & Link 1999). However, 91 
the efficacy of targeting cancer cells by hNIS radioiodine gene therapy and thereby modifying 92 
antitumor immunity has not been systematically investigated in here. 93 
Normally, intradermal (i.d.) injection (Yu et al., 1999) induces antigen-specific Th2 94 
immune responses. However, in the present study, we performed repeated i.d. injections 95 
(Michael et al. 1999; Shedlock & Weiner, 2000) of a naked DNA vaccine consisting of plasmid 96 
DNA encoding hNIS and the lacZ gene as a marker to induce Th1 response. We monitored the 97 
distribution and persistence of gene expression and evaluated the capacity for inducing specific 98 
Th1 immune responses in the context of a Th2-dominant immune profile. We found that an 99 
anti-LacZ humoral and anti-hNIS Th1 immune responses were induced by repeated i.d. 100 
immunizations and the use of non-secreted proteins encoding genes that solve immune 101 
deviation (Son et al., 2016b). 102 
 103 
 104 
Materials and Methods 105 
Plasmid DNA 106 
The hNIS-expressing vector pcDNA3.1-FL-hNIS vector (pcDNA-hNIS) expressing hNIS 107 
under the control of the cytomegalovirus (CMV) promoter and the neomycin resistance cassette 108 
from the simian virus 40 promoter was provided by Dr. S. Jhiang (Ohio State University, 109 
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Columbus, OH, USA). The pCMVβ vector expressing β-gal was purchased from Clontech 110 
(Mountain View, CA, USA). Plasmids were amplified in Escherichia coli DH5α cells and 111 
purified using endotoxin-free Giga Prep columns (Qiagen, Valencia, CA, USA). 112 
Detection of enhanced green fluorescent protein plasmid (pEGFP) in CT26 cells 113 
The day before transfection, CT26 cells grown in a 75-cm2 flask were trypsinized, and 10% of 114 
each cell line was mixed in 18 ml of Medium 199 (Hyclone, Logan, UT, USA) supplemented 115 
with 10% fetal bovine serum (FBS); 3 ml of this cell suspension was seeded into one well of a 116 
6-well plate using Transfast reagent (Promega, Madison, WI, USA) according to the 117 
manufacturer’s instructions. Briefly, 2 ml of the reagent and 1 mg of pEGFP plasmid were 118 
mixed and incubated at room temperature for 15 min. The mixture was added to the cells and 119 
6 h later, the DNA-transfection mixture was replaced with Medium 199. After 48 h, 120 
fluorescence was detected by using flow cytometry on a FACSAria instrument (BD 121 
Biosciences, San Jose, CA, USA). 122 
 123 
β-gal staining of transfected CT26 cells 124 
The plasmid encoding lacZ was transfected as described above. Cells were then washed three 125 
times for 5 min at room temperature and then fixed in a solution of 2% formaldehyde and 0.2% 126 
glutaraldehyde in phosphate-buffered saline (PBS; pH 7.6–7.8) for 5 min at room temperature. 127 
After rinsing with PBS, substrate solution (1 mg/ml X-gal substrate; Sigma-Aldrich, 128 
Deisenhofen, Germany) was added, followed by incubation at 37°C for 6 h. Transfection 129 
efficiency was visually confirmed. 130 
 131 
Detection of hNIS expression in CT26 cells 132 
The plasmid encoding NIS DNA was transfected as described above. The ability of transfected 133 
cells to concentrate 99mTc or 131I was determined as previously described [14]. Briefly, CT26 134 
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cells (5 × 104) were seeded in 24-well plates and cultured in Dulbecco’s Modified Eagle’s 135 
Medium (DMEM) containing 10% FBS for 24 h. 125I uptake was determined by incubating 136 
cells with 500 μl of Hank’s balanced salt solution (bHBSS; Gibco, Grand Island, NY, USA) 137 
containing 3.7 kBq of carrier-free 125I and 10 μM sodium iodide (NaI) at 37°C for 30 min to 138 
obtain a specific activity of 740 MBq/mmol (20 mCi/mmol). The cells were quickly washed 139 
twice with bHBSS and detached using 500 μl trypsin. Radioactivity was measured using a 140 
gamma counter (CobraII Packard; PerkinElmer, Waltham, MA, USA). 141 
 142 
Immunization 143 
Specific pathogen-free female BALB/c mice (6 weeks old) were obtained from SLC Japan 144 
(Hamamatsu, Japan) and were handled according to the guidelines issued by the Seoul National 145 
University Animal Research Committee. For in vivo tracking of plasmid vectors, 100 μg of 146 
pCMV-LacZ or pcDNA-hNIS resuspended in 50 μl endotoxin-free Tris-147 
ethylenediaminetetraacetic acid buffer (Qiagen) were administered by i.d. injection into the 148 
thigh of mice using a 30-G insulin syringe (BD Biosciences, Franklin Lakes, NJ, USA). To 149 
identify tumor-protective or antigen-specific cellular immune responses, mice were immunized 150 
three times at 2-week intervals in the hind leg with hNIS DNA or in the dorsal skin with lacZ 151 
DNA. Mice were anesthetized by intraperitoneal injection of 0.3 ml of a 1:1:9 solution of 152 
rompun, (Parke-Davis, Detroit, MI, USA), ketamine (Bayer, Leverkusen, Germany), and saline 153 
(RKS solution). 154 
 155 
PCR detection of lacZ and hNIS plasmid DNA 156 
PCR primers were designed to amplify the lacZ gene in dorsal skin and hNIS gene in various 157 
organs, including the draining lymph nodes (dLNs), non-dLNs, spleen, muscle, liver, and heart. 158 
The forward and reverse sequences were as follows: lacZ, 5'-159 
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TTCACTGGCCGTCGTTTTACAACGTCGTGA-3' and 5'-160 
ATGTGAGCGAGTAACAACCCGTCGGATTCT-3'; and hNIS, 5'- 161 
AGATGAGCTGACACGGAACAG-3' and 5'-CTGGGGAAAAGTGGGAAAAAGAG-3'. 162 
Expression levels were normalized to that of β-actin (5'-CTGTGCTATCCCTGTACGCC-3' 163 
and 5'-ATGTGACAGCTCCCCACACA-3'). The 50-μl reaction contained 5 μl PCR buffer, 50 164 
nM each dNTP, 5 nM forward and reverse primers, and 1 U Taq DNA polymerase. The PCR 165 
conditions were as follows: 94°C for 5 min; 35 cycles of 94°C for 45 s, 63°C for 45 s, and 72°C 166 
for 45 s; and72°C for 7 min. PCR products were resolved on a 2% agarose gel and visualized 167 
under ultraviolet light. PCR conditions for transgene amplification were as follows: 34 cycles 168 
of 94°C for 60 s, 55°C for 60 s, and 72°C for 60 s. 169 
 170 
hNIS reverse transcription (RT)-PCR 171 
Organs were removed from immunized mice and lysed using a homogenizer. Total RNA was 172 
extracted from lysates in the presence of RNase inhibitors using TRIzol reagent (Molecular 173 
Research Center, Cincinnati, OH, USA). Isolated RNA was dissolved in diethyl pyrocarbonate-174 
treated water (Sigma-Aldrich, St. Louis, MO, USA) and used to generate cDNA using a 15-175 
mer poly dT oligonucleotide (Invitrogen, Carlsbad, CA, USA) and Superscript reverse 176 
transcriptase (Gibco) with incubation at 37°C for 1 h according to the manufacturer’s protocol. 177 
Expression of the hNIS gene was detected in dLNs, non-dLNs, and spleen by RT-PCR using 178 
the primers: 5'-GGCTCCTCGGTGACTCTAGGATGC-3' (forward) and 5'-179 
CATGAATTCTGGGCTCAATTTTCTTGTCC-3' (reverse). To confirm DNA integrity, the 180 
mouse β-actin gene (codons 135–223) was amplified with the primers 5'-181 
GGCTCCTCGGTGACTCTAGGATGC-3' (forward) and 5'-182 
CATGAATTCTGGGCTCAATTTTCTTGTCC-3' (reverse) under the following conditions: 34 183 




Whole-body imaging and nuclear scintigraphy of hNIS DNA-immunized mice 186 
At designated times (2, 16, and 24 h and 2, 3, and 11 days) following injection of pcDNA-187 
hNIS, mice were administered 300 μCi of 99mTc (11.1 MBq) by intraperitoneal injection and 188 
anesthetized with 0.3 ml of RKS solution; 30 min later, mice were placed in a prostrate position 189 
and scanned with a gamma camera (ON 410; Ohio Nuclear, Solon, OH, USA) equipped with 190 
a pinhole collimator. Relative radioactivity was assessed in the entire body over a period of 5 191 
min, and dynamic frames were obtained; 1 h later, LNs, spleen, liver, and skin near the injection 192 
site were removed from each mouse and weighed to determine the organ distribution patterns 193 
of injected DNA; blood samples were also collected. Tissues were stored at −70°C for 16 h, 194 
after which 99mTc uptake was measured using a gamma counter. 195 
 196 
Antibody measurements by enzyme-linked immunosorbent assay (ELISA) 197 
Antibody titers in sera obtained from mice at the end of the experiment were determined by 198 
ELISA. Briefly, 96-well microtiter plates were coated overnight with 1 mg β-galatosidase (5 199 
mg/ml) in 0.1 M carbonate buffer (pH 9.5) for detection of anti-β-gal antibodies. To determine 200 
anti-NIS antibody titer, 96-well microtiter plates were coated with 1 × 104 irradiated CT26 or 201 
CT26/NIS cells in 0.01 M PBS (pH 7.5). After washing with wash buffer (PBS with 0.05% 202 
Tween-20 [pH 7.4]), the plates were blocked overnight with assay diluent (BD Pharmingen, 203 
San Diego, CA, USA). After washing with wash buffer, eight consecutive 1:3 dilutions of 204 
serum sample in assay diluent initially diluted 1:20, 1:40, and 1:100 (for detection of anti-β-205 
gal antibodies) were added to the wells. After 2 h of incubation at room temperature, the plates 206 
were washed with wash buffer and incubated for 1 h at room temperature with horseradish 207 
peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin (Ig; Southern Biotechnology 208 
Associated, Birmingham, AL, USA). HRP-conjugated goat anti-mouse IgG1 or IgG2a 209 
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(Southern Biotechnology Associated) were used to determine the isotype of the antibodies. 210 
After washing, 100 μl of substrate solution (tetramethylbenzidine and hydrogen peroxide; BD 211 
Pharmingen) were added, and the plate was incubated in the dark for 30 min at room 212 
temperature. The reaction was terminated by adding 1 M H2SO4 and absorbance was measured 213 
at 450 nm on an ELISA plate reader. To calculate anti-NIS and total antibodies titers, purified 214 
mouse IgG2a or IgG1 monoclonal antibodies were included in the plates. 215 
 216 
Enzyme-linked immunospot (ELISpot) assay 217 
Th1 interferon (IFN)-γ or Th2 interleukin (IL)-4 secretion by stimulated T cells were evaluated 218 
with commercially available ELISpot assay kits (Diaclone, Besançon, France) according to the 219 
manufacturer’s protocol. Briefly, PVDF polyvinylidene difluoride 96-well plates were 220 
incubated overnight at 4°C with an anti-mouse IFN-γ or -IL-4 (capture) antibody. The 221 
following day, freshly isolated NIS-immunized LN cells (5 × 105 responder cells/well) were 222 
washed and resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium containing 223 
10% fetal calf serum and then incubated in anti-INF-γ or -IL-4 antibody-pre-coated 96-well 224 
plates at 37°C for 20 h. The cells were removed, and biotinylated anti-mouse IFN-γ or IL-4 225 
(detection) antibodies were added followed by streptavidin-conjugated alkaline phosphatase, 226 
which converted the substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium to 227 
a blue dye. Spots were counted using the Bioreader system (BIO-SYS GmbH, Karben, 228 
Germany). 229 
 230 
Cytokine ELISA 231 
LNs were removed and single-cell suspensions were obtained by gentle pipetting. 232 
Lymphocytes were washed and resuspended in RPMI 1640 medium supplemented with 10% 233 
heat-inactivated FBS, 2 mM L-glutamine, 200 mg/ml streptomycin, 200 U/ml penicillin, and 234 
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0.1% 2-mercaptoethanol. Cells were seeded in 24-well tissue culture plates at a final 235 
concentration of 2 × 106/ml in enriched RPMI 1640 medium, and stimulated by co-culturing 236 
with irradiated CT26 or CT26/NIS cells for 72 h at 37°C in an atmosphere of 5% CO2. IL-4 237 
and INF-γ levels in culture supernatants of LN cells stimulated with irradiated CT26 or 238 
CT26/NIS cells were measured using OptEIA mouse IFN-γ or IL-4 ELISA kits (BD 239 
Pharmingen) according to the manufacturer’s instructions. 240 
 241 
Tumor challenge 242 
At 2 weeks after the final hNIS DNA injection, mice were challenged by subcutaneous injection 243 
into the fore leg of 5 × 105 (left) or 1 × 105 (right) CT26/NIS cells resuspended in 100 μl of 244 
10% FBS in DMEM. Tumor dimensions were measured twice a week, and tumor volume was 245 
calculated as horizontal length (mm) × vertical length (mm) × depth (mm) = volume (in mm3). 246 
 247 
In vivo tumor imaging 248 
At indicated times after injection of pcDNA NIS into CT26/NIS tumors, 37 MBq of 99mTc was 249 
injected into the tail of mice and static SPECT images were acquired after 10 min using a 250 
gamma camera (GE Healthcare, Waukesha, WI, USA) with a low-energy, high-resolution 251 
collimator. 252 
 253 
Biodistribution study 254 
Mice were sacrificed at the end of the single-photon emission computed tomography (SPECT) 255 
scan (90-min time point). Blood, heart, liver, spleen, lung, kidneys, thyroid, stomach, intestine, 256 
muscle, bone, and tumor were harvested and weighed. Radioactivity was measured with a 257 






Efficiency of plasmid DNA expression 262 
We evaluated the transfection efficiency of each plasmid into CT26 murine colon cancer cells 263 
(H-2d; syngeneic in BALB/c mouse strain). EGFP expression was detected by flow cytometry 264 
(Fig. 1A). LacZ in CT26 cells was visible as a green color (Fig. 1B). The transfection efficiency 265 
was confirmed with pcDNA3.1-hNIS by detecting 99mTc with a gamma counter (Fig. 1C). 266 
These results demonstrate that the plasmid vectors are able to transfect cells. 267 
 268 
β-gal is expressed in mouse tissues following pCMV-LacZ inoculation 269 
X-gal is an organic compound composed of galactose linked to indole that is commonly used 270 
to test for the presence of β-gal according to a color change to blue/green. We monitored β-gal 271 
expression in mouse skin following i.d. injection of pCMV-LacZ by X-gal staining. Although 272 
there was no spread of the blue dye beyond the injection site (Fig. 2A, left panel), the green 273 
color corresponding to X-gal was detected far away from the injection site from 2 h to 30 days 274 
post-injection (Fig. 2A, right panel), suggesting that the plasmid encoding the lacZ gene was 275 
taken up by resident cells (most likely keratinocytes or APCs) that then migrated out of the 276 
injection site. We next evaluated the levels of pCMV-LacZ DNA injected into the dorsal skin, 277 
which was divided into three sites (Fig. 2B, upper): sections 1, 2, and 3 represent the upper, 278 
middle, and lower sites of injection, respectively. The PCR analysis revealed that DNA had 279 
moved from the injection site throughout the body up until 10 days after injection (Fig. 2B, 280 
lower). LacZ DNA was still detected at the injection site at 15 and 30 days. 281 
 282 
hNIS gene is expressed in mouse tissues following DNA inoculation 283 
Our data suggested that cells transfected with plasmid DNA and injected into mice could 284 
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migrate away from the injection site. We therefore evaluated the expression of hNIS DNA in 285 
various immune tissues of mice (LN and spleen) and other organs (muscle, heart, and liver) 286 
following i.d. injection. hNIS DNA was expressed in lymph nodes as early as 2 h post-injection 287 
and in the spleen after 3 days, with expression persisting up to day 18; at 2 h, hNIS DNA was 288 
detected in muscle tissues at the injection site (Fig. 3A). An RT-PCR analysis showed that hNIS 289 
was expressed as early as 2 h post-injection in the LN and after 1 day in the spleen, with 290 
expression persisting up to 18 days; in contrast, mock transfectants showed no hNIS expression 291 
(Fig. 3B). 292 
To monitor NIS expression, we dissected the organs and detected γ-rays with a gamma 293 
counter. At 2 h post-injection, γ-ray levels were highest at the injection site (skin) relative to 294 
the mock-injected group (Fig. 4A). Up to 11 days after DNA injection, 99mTc uptake was highest 295 
in lingual LNs (dLN), followed by the LN (non-dLN) and spleen (Fig. 4B, C). To quantify the 296 
level of radioactivity in vivo, regions of interest in the scintigraphic images were analyzed at 297 
various time points (2, 8, 16, and 24 h and 11 days) after immunization. Whole-body relative 298 
radioactivity levels adjacent to the injection site were higher in mice immunized with hNIS 299 
plasmid as compared to mock-injected control mice (Fig. 4D). As expected, hNIS gene 300 
expression was detected in the LN and spleen for up to 11 days. 301 
 302 
Humoral and cellular responses induced by repeated i.d. injections of lacZ and hNIS DNA 303 
Determining the mechanism by which DNA vaccines stimulate the immune response is critical 304 
for identifying the type of immune response that is induced [19, 20]. While i.d. delivery will 305 
firstly elicit the humoral response with the release of IgA and IgG1, the intramuscular route has 306 
been shown to prime cellular responses by activation of cytotoxic T lymphocytes (CTLs) and 307 
production of IgG2a. We therefore evaluated antibody responses against lacZ. Anti β-gal 308 
antibodies were generated at 10 days, with the levels reaching a peak at 15 days post-309 
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immunization (Fig. 5A). The antibody subclass was assessed by ELISA by coating the wells 310 
with NIS-expressing CT26 cells and adding serum from mice immunized with pcDNA or hNIS 311 
DNA. The results show that the anti-NIS antibodies generated were of the IgG2a (Th1) isotype 312 
(Fig. 5B). 313 
 314 
hNIS DNA vaccination induces a strong Th1 cytokine profile 315 
The ELISpot assay was used to evaluate the secretion of IFN-γ and IL-4 by cells isolated from 316 
dLNs, non-dLNs, mesenteric (M) LNs and spleen after NIS DNA immunization. To assess 317 
hNIS-specific T cell responses, splenocytes and LN cells were isolated 10 days after the final 318 
injection. IFN-γ was secreted at a high level by cells from the dLN and to a lesser extent by 319 
MLN and non-dLN cells; the spleen also showed a specific anti-NIS IFN-γ response (Fig. 6A). 320 
IL-4 was not detected. These data were confirmed by in vitro stimulation of spleen, dLN, and 321 
non-dLN cells with irradiated CT26/NIS cells and measurement of cytokine secretion by 322 
ELISA. Similar to the results of the ELISpot assay, high levels of IFN-γ were secreted by cells 323 
of dLNs relative to non-dLN and spleen, with no IL-4 secretion (Fig. 6B). 324 
 325 
Protective tumor immunity induced by DNA immunization 326 
We investigated whether immunization of mice with hNIS DNA conferred protection against 327 
tumors expressing NIS. Mice were subcutaneously inoculated with CT26/NIS tumor cells 2 328 
weeks after the final hNIS DNA injection (Fig. 7A). Mice immunized with hNIS DNA showed 329 
significant retardation of tumor growth relative to those injected with pcDNA3 (Fig. 7B). 330 







Plasmid DNA injection can lead to transgene expression in vivo (Wolff et al., 1990; Chen et 336 
al.,, 2013; Han et al., 2015). However, immune responses induced by DNA vaccines have not 337 
been extensively, although they are thought to be similar to the viral infection process. 338 
Immediately after injection, plasmid DNA enters cells—mainly keratinocytes and APCs 339 
(Tonheim, Bogwald & Dalmo, 2008)—and is transported to the nucleus. The transgene is 340 
transcribed and then translated into a protein that is presented by MHC-I or -II to the host 341 
immune system. The protein may then be engulfed and degraded, while transgene peptide-342 
loaded APCs can migrate to dLNs to activate naïve T cells (Son et al., 2016). 343 
In this study, we found that the transgene spread far from the site of injection following 344 
in vivo inoculation and was detected up to 30 days post-inoculation. The transgene-expressing 345 
cells migrated primarily into immune organs such as dLNs, suggesting that the cells are APCs 346 
that home to immune organs to activate an inflammatory signal, or else keratinocytes that are 347 
targets for the immune response. In the LNs, Th cells activated by transgene-expressing APCs 348 
secrete cytokines that can activate B cells to induce an anti-β-gal humoral response and the 349 
production of IgG2a anti-NIS antibodies by isotype switching (Boland et al., 2000). Antigen-350 
binding B cells are trapped in the T cell-rich zone of dLNs and are activated by encounters with 351 
activated Th cells. Antibody isotype switching is stimulated by multiple cytokines. IL-4 352 
induces a switch to IgG1 and IgE, whereas transforming growth factor (TGF)-β causes a switch 353 
to IgG2b and IgA. Th2 cells secrete IL-4 and -5 and TGF-β, which induce IgA. Although Th1 354 
cells are poor initiators of antibody responses, they release IFN-γ for antibody isotype 355 
switching to IgG2a and IgG3 (Janeway et al., 2001). In our study, we confirmed IgG2a 356 
switching after DNA vaccination, which corresponded to an increase in IFN-γ levels. It is 357 
possible that antibody isotype switching ultimately leads to tumor killing by the Th1 response, 358 
which activates cytotoxic T cells. Soluble or secreted vaccine antigens may be phagocytosed 359 
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by APCs immediately following DNA vaccination and enter the MHC class II exogenous 360 
pathway. We therefore used a cellular (LacZ) or transmembrane (NIS) protein to exclude direct 361 
APC uptake immediately after translation that could deviate into Th2-type immune responses. 362 
We also administered two booster injections to re-activate cellular immunity. The immune 363 
response to the first immunization was predominantly humoral; however, memory T cells were 364 
subsequently recruited to the injection site, which stimulated a Th1-type immune response (Son 365 
et al., 2016b). Repeated immunization (boosting) involves dendritic cells (DCs), but it is 366 
unclear how frequently booster injections should be administered. In fact, a homologous prime-367 
boost strategy may not be ideal, as antigen-bearing DCs were shown to be eliminated by 368 
effector and memory CTLs in vaccinated mice (Yang et al., 2006). 369 
CD8+ T cells can lyse cells presenting transgenic peptide on MHC-I molecules, 370 
resulting in increased antigen release. Furthermore, CD4+ T cells (Th2 response) can activate 371 
immature DCs that home to LNs and stimulate B and T cells (Reyes-Sandoval and Ertl, 2001), 372 
thereby repeating the cycle of activation. Thus, both humoral and cellular immunity are primed 373 
for the next challenge although CD8+ T cells must be induced to lyse tumor cells. It was 374 
previously shown that i.d. injection can result in a Th2-type profile (Shedlock and Weiner, 375 
2000), but in this study we observed that humoral immunity could be induced to switch to Th1-376 
type immunity (IgG2a). Furthermore, IFN-γ was significantly induced in the transgene-377 
immunized group relative to controls, which protected the mice from tumor challenge. The 378 
presumed mechanism is shown in Figure 8. 379 
Although DNA vaccines can induce cellular responses, the injection route is an 380 
important determinant of the type of response. A Th2 response is typically induced by i.d. 381 
injection of DNA (Shedlock & Weiner, 2000), posing a challenge for the widespread use of 382 
DNA vaccines. In this study, we solved this problem by inhibiting the Th2 response through 383 
IgG1 to IgG2a switching. We selected an intracellular antigen that can be loaded onto MHC-I 384 
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to activate the Th1 response and administered repeated, which could induce memory T cells 385 
and can easily stimulate a Th1-type response. Additional studies are needed to determine 386 
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Figure legends 475 
 476 
Figure 1. In vitro expression of various plasmid DNAs in CT26 cells. (A) Transfection 477 
efficiency and eGFP expression were evaluated by flow cytometry 48 h after transfection. (B) 478 
X-gal staining was performed following pCMV-LacZ transfection. (C) 99mTc uptake was 479 
measured using a gamma counter 48 h after transfection of pcDNA-hNIS into the cells. Three 480 








Figure 2. In vivo X-gal staining and detection of lacZ DNA uptake by cells. Mice received 487 
i.d. injection of 100 μg pCMV-LacZ DNA and in vivo plasmid DNA trafficking was monitored. 488 
(A) LacZ protein was detected by X-gal staining at the indicated times. (B) RT-PCR was used 489 
to monitor the movement of lacZ DNA taken up by cells. The whole dorsal skin was divided 490 











Figure 3. In vivo expression of hNIS DNA following injection. (A) The movement of hNIS-500 
expressing cells and transgene expression was monitored by RT-PCR analysis dLNs, non-dLNs, 501 
spleen, lingual muscle, liver, and heart following hNIS DNA injection at the indicated time. (B) 502 




Figure 4. Trafficking of plasmid DNA. γ-Rays were detected using a gamma counter (A) 2 h, 505 
(B) 11 days, and (C) 0–11 days after hNIS DNA injection into mice. Immune organs (LNs and 506 
spleen), lingual muscle, and lingual skin near the injection site were monitored. (D) Whole-507 




Figure 5. Humoral immunity after DNA vaccination. (A) Serum antibody specific for β-gal. 510 
Serum samples were diluted 1/20, 1/40, and 1/100. (B) IgG1 and IgG2a titers against NIS in 511 
the sera of hNIS DNA-immunized mice. At 10 days after final injection of hNIS DNA (6 weeks 512 
after the first immunization), serum samples were collected and anti-NIS IgG1 and IgG2a titers 513 
were determined by ELISA. IgG1 or IgG2a levels in the serum of pCDNA-NIS- or pCDNA-514 




Figure 6. Cellular immunity following DNA vaccination. (A) ELISpot detection of IFN-γ- 517 
or IL-4-expressing cells. LNs were collected from hNIS DNA-immunized mice and immune 518 
cells were isolated with a needle. Cells were cultured for 48 h and IFN-γ or IL-4 levels in the 519 
supernatant were determined. (B) Cytokine ELISA detection of IFN-γ or IL-4 in the 520 
supernatant of immune cell cultures; the cells were re-activated with irradiated CT26-NIS cells 521 




Figure 7. Decrease in tumor growth rate by hNIS DNA immunization. (A) Tumor 524 
inoculation scheme. (B) Tumor retardation after NIS immunization. Left panel shows tumor 525 
growth following inoculation of the fore leg with 1 × 105 CT26/NIS cells; right panel shows 526 




Figure 8. Summary of DNA immunization. Schematic representation of the mechanism by 529 
which DNA immunization results in DNA uptake and cell migration. 530 
